Biosimilars Chemotherapy Magazine 
Pharmaceutical Technology
JULY 1, 2025
Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence.
Pharmaceutical Technology
JULY 4, 2025
Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Biosimilars and generics flood the market upon patent loss, which exerts pricing pressure on the branded product. There has been a push by the Trump administration to increase biosimilar and generic drug use in the US.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 4, 2025
Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU). Clinical trials have demonstrated that both biosimilars match the reference product’s safety, quality and efficacy standards.
Pharmaceutical Technology
JULY 7, 2025
Find out more J&J’s drug is an option for patients where medical or surgical treatment to lower testosterone levels has not worked, and in those who have BRCA 1/2 mutations – a subset of homologous recombination repair (HRR) mutations – in whom chemotherapy is not indicated.
pharmaphorum
JULY 18, 2025
Find out more about the event here: [link] Image 18 July, 2025 Hanson Wade Bookmark this Oncology Taking chemotherapy directly to skin lesions, with Dr Raza B. Finding the right chemical start points is crucial to help you save time and costs in the long run.
pharmaphorum
JULY 1, 2025
The new data comes from the FORTITUDE-101 looking at bemarituzumab plus chemotherapy as a front-line therapy for FGFR2b-positive advanced gastric cancer, and has revealed a significant improvement in overall survival (OS) compared to placebo plus chemo. Digital Sponsored Axtria Ignite 2025: Jaswinder Chadha on driving life science.
Expert insights. Personalized for you.
52 
Let's personalize your content